Topic:

M&A

Latest Headlines

Latest Headlines

Why didn't J&J buy Imbruvica partner Pharmacyclics? It wants hot drugs cheap, CEO says

Why didn't Johnson & Johnson buy Pharmacyclics? Good question--and one The Wall Street Journal posed to CEO Alex Gorsky in a recent interview in Tokyo.

Amgen CEO Bradway collects a $14M pay package on record-breaking revenue

In a year when several of his peers won big payoffs for one extraordinary reason or another, Amgen CEO Robert Bradway earned just about as much as he had the previous year, give or take a few hundred thousand. Small comfort--though some comfort, perhaps--to the thousands of employees facing job cuts as Amgen prepares for biosimilar competition to its top-selling meds.

Valeant starts $500M in Salix cost-cutting with 250 layoffs

After closing its deal for Salix Pharmaceuticals, Valeant wasted no time getting down to business with the cost-cutting it's known for. And now, North Carolina's Triangle area has another 250-plus pharma layoffs to add to a growing list.

Medtronic grabs artificial pancreas tech from Israeli devicemaker

Medtronic snatched up artificial pancreas technology from Israel-based DreaMed Diabetes for its insulin pumps, the company's latest deal as it looks to diversify its diabetes offerings and cash in on a growing market.

Medtronic expands services push to diabetes care with acquisition of Diabeter

Med tech company executives often talk about the need to provide not just products but "solutions" to problems like meeting Affordable Care Act metrics at hospitals and lowering the cost of patient care. Now, Medtronic is expanding its push into healthcare services to a new front with the acquisition of the Netherlands' diabetes and research clinic Diabeter.

Watch out, pharma. Fitch says the M&A party could come with a hangover

Biopharma has been on a bona fide dealmaking binge. Trouble is, that binge is starting to get too expensive--and too risky. That's what Fitch Ratings says in a new report that cautions against fast-and-loose dealmaking.

Boston Scientific buys endoscopic ultrasound pancreatic treatment startup for $75M+

Boston Scientific added to an existing strength in endoscopy by acquiring Xlumena for up to $75 million plus undisclosed sales milestones.

Piramal sells its CRO division to India's Indoco

Indian conglomerate Piramal has sold off its CRO business to Indoco Remedies, getting rid of a business "not considered strategic in nature," according to the company.

Orthofix restates earnings, gains option to buy migraine device startup eNeura for $65M+

Orthofix has secured an 18-month option to buy eNeura with a $15 million loan. The financing is designed to support the commercialization of the startup's Spring TMS device that FDA cleared last May and is the first portable device available in the U.S. to treat acute pain associated with migraine headache with aura, according to the company.

What's an Allergan career worth? $534M in cash, if you're ex-CEO David Pyott

Actavis' agreement to buy Allergan for $66 billion put then-Allergan CEO David Pyott in line for a hefty payout in cash and shares--and now that the tie-up is official, he's collecting.